| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-07 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-06 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.25 | 2e-06 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.28 | 2e-06 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.18 | 9e-06 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.38 | 2e-05 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.17 | 2e-05 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-05 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.24 | 4e-05 |